Rose Bengal
Phase 3Small molecule
Rose Bengal is one of 4 small molecule programs targeting Bacterial Keratitis. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Bacterial Keratitis
#DrugCompanyPhaseTrials
1Avelox
BayerPhase 3
Durezol
NovartisPhase 3
Rose Bengal
UUniversity of California, San Francisco
Phase 3
Moxifloxacin Ophthalmic
UUniversity of California, San Francisco
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rose Bengal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details